Publications

BibTex format

@article{Allione:2023:10.1002/ijc.34339,
author = {Allione, A and Viberti, C and Cotellessa, I and Catalano, C and Casalone, E and Cugliari, G and Russo, A and Guarrera, S and Mirabelli, D and Sacerdote, C and Gentile, M and Eichelmann, F and Schulze, MB and Harlid, S and Eriksen, AK and Tjønneland, A and Andersson, M and Dollé, MET and Van, Puyvelde H and Weiderpass, E and Rodriguez-Barranco, M and Agudo, A and Heath, AK and Chirlaque, M-D and Truong, T and Dragic, D and Severi, G and Sieri, S and Sandanger, TM and Ardanaz, E and Vineis, P and Matullo, G},
doi = {10.1002/ijc.34339},
journal = {International Journal of Cancer},
pages = {725--737},
title = {Blood cell DNA methylation biomarkers in preclinical malignant pleural mesothelioma: the EPIC prospective cohort},
url = {http://dx.doi.org/10.1002/ijc.34339},
volume = {152},
year = {2023}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer mainly caused by asbestos exposure. Specific and sensitive non-invasive biomarkers may facilitate and enhance screening programs for the early detection of cancer. We investigated DNA methylation (DNAm) profiles in MPM pre-diagnostic blood samples in a case-control study nested in the European Prospective Investigation into Cancer and nutrition (EPIC) cohort, aiming to characterise DNAm biomarkers associated with MPM. From the EPIC cohort, we included samples from 135 participants who developed MPM during 20 years of follow up and from 135 matched, cancer-free, controls. For the discovery phase we selected EPIC participants who developed MPM within five years from enrolment (n=36) with matched controls. We identified nine differentially methylated CpGs, selected by 10-fold cross-validation and correlation analyses: cg25755428 (MRI1), cg20389709 (KLF11), cg23870316, cg13862711 (LHX6), cg06417478 (HOOK2), cg00667948, cg01879420 (AMD1), cg25317025 (RPL17) and cg06205333 (RAP1A). Receiver operating characteristic (ROC) analysis showed that the model including baseline characteristics (age, sex, PC1wbc) along with the nine MPM-related CpGs has a better predictive value for MPM occurrence than the baseline model alone, maintaining some performance also at more than five years before diagnosis [AUC (area under the curve) < 5 years=0.89; AUC 5-10 years=0.80; AUC >10 years=0.75; baseline AUC range=0.63-0.67)]. DNAm changes as non-invasive biomarkers in pre-diagnostic blood samples of MPM cases were investigated for the first time. Their application can improve the identification of asbestos-exposed individuals at higher MPM risk in order to possibly adopt more intensive monitoring for early disease identification.
AU  - Allione,A
AU  - Viberti,C
AU  - Cotellessa,I
AU  - Catalano,C
AU  - Casalone,E
AU  - Cugliari,G
AU  - Russo,A
AU  - Guarrera,S
AU  - Mirabelli,D
AU  - Sacerdote,C
AU  - Gentile,M
AU  - Eichelmann,F
AU  - Schulze,MB
AU  - Harlid,S
AU  - Eriksen,AK
AU  - Tjønneland,A
AU  - Andersson,M
AU  - Dollé,MET
AU  - Van,Puyvelde H
AU  - Weiderpass,E
AU  - Rodriguez-Barranco,M
AU  - Agudo,A
AU  - Heath,AK
AU  - Chirlaque,M-D
AU  - Truong,T
AU  - Dragic,D
AU  - Severi,G
AU  - Sieri,S
AU  - Sandanger,TM
AU  - Ardanaz,E
AU  - Vineis,P
AU  - Matullo,G
DO  - 10.1002/ijc.34339
EP  - 737
PY  - 2023///
SN  - 0020-7136
SP  - 725
TI  - Blood cell DNA methylation biomarkers in preclinical malignant pleural mesothelioma: the EPIC prospective cohort
T2  - International Journal of Cancer
UR  - http://dx.doi.org/10.1002/ijc.34339
UR  - https://www.ncbi.nlm.nih.gov/pubmed/36305648
UR  - https://onlinelibrary.wiley.com/doi/10.1002/ijc.34339
UR  - http://hdl.handle.net/10044/1/100557
VL  - 152
ER  -

Download

ProfessorPaoloVineis

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)